Beneficial Effects of Olmesartan and Temocapril on Urinary Liver-Type Fatty Acid-Binding Protein Levels in Normotensive Patients With Immunoglobin A Nephropathy

American Journal of Hypertension

Volumn 20, Issue 11, 2007, Pages 1195-1201

  Nakamura, Tsukasa ^a   Inoue, Teruo ^b   Sugaya, Takeshi ^c   Kawagoe, Yasuhiro ^a   Suzuki, Tsukasa ^a   Ueda, Yoshihiko ^d   Koide, Hikaru ^e   Node, Koichi ^b  

^a Shinmatsudo Central General Hospital   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c RIKEN KOBE INSTITUTE   (Japan)

^d DOKKYO MEDICAL UNIVERSITY   (Japan)

^e KOTO HOSPITAL   (Japan)

Author keywords

angiotensin receptor blocker; angiotensin converting enzyme inhibitor; liver type fatty acid binding protein; Proximal tubule

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID BINDING PROTEIN; OLMESARTAN; TEMOCAPRIL;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY TUBULE DAMAGE; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DEOXYGUANOSINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY ACID-BINDING PROTEINS; FEMALE; GLOMERULONEPHRITIS, IGA; HEART RATE; HUMANS; IMIDAZOLES; MALE; PROTEINURIA; TETRAZOLES; THIAZEPINES;

EID: 35348906625     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2007.06.003     Document Type: Article

References (30)

1. Bantis C., Ivens K., Kreusser W., Koch M., Klein-Vehne N., Grabensee B., and Heering P. Influence of genetic polymorphisms of the rennin-angiotensin system on IgA nephropathy. Am J Nephrol 24 (2004) 258-267
2. Russo P., Minutolo R., and Pisani A. Co-administration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 38 (2001) 18-25
3. Hilgers K.F., and Mann J.F. ACE inhibitors versus AT1 receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 13 (2002) 1100-1108
4. Tanaka H., Suzuki K., Nakahata T., Tsugawa K., Konno Y., Tsuruga K., Ito E., and Waga S. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy. Pediatr Int 46 (2004) 576-579
5. Homma K., Hayashi K., Kanda T., Yoshioka K., Takematsu I., Tatematsu S., Kumagai H., Wakino S., and Saruta T. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease. J Hum Hypertens 18 (2004) 879-884
6. Horita Y., Tanaka K., Taguchi T., Furusu A., and Kohno S. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology 11 (2006) 462-466
7. Agarwal R. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am J Physiol Renal Physiol 284 (2003) F863-F869
8. Kamijo A., Kimura K., Sugaya T., Yamanouchi M., Hikawa A., Hirano N., Goto A., and Omata M. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 143 (2004) 23-30
9. Kamijo A., Sugaya T., Hikawa A., Yamanouchi M., Hirata Y., Ishimitsu T., Numabe A., Takagi M., Hayakawa H., Tabei F., Sugimoto T., Mise N., and Kimura K. Clinical evaluation of urinary excretion of liver-type fatty acid binding as a marker for the monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med 145 (2005) 125-133
10. Nakamura T., Sugaya T., Ebihara I., and Koide H. Urinary liver-type fatty acid-binding protein: discrimination between IgA nephropathy and thin basement membrane nephropathy. Am J Nephrol 25 (2005) 447-450
11. Xa G.W., Yao O.H., and Weng O.F. Study of urinary 8-hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic nephropathy. J Pharm Biomed Anal 36 (2004) 101-104
12. Hata I., Kaji M., and Hirano S. Urinary oxidative stress markers in young patients with type 1 diabetes. Pediatr Int 48 (2006) 58-61
13. Saito S., Yamauchi H., Hasui Y., Kurashige J., Ochi H., and Yoshida K. Quantitive determination of urinary 8-hydroxy deoxyguanosine (8-OHdG) by using ELISA. Res Commun Mol Pathol Pharmacol 107 (2000) 39-44
14. Nieuwhof C., Kruytzer M., Frederiks P., and van Breda Vnesman P.J.C. Chronicity index and mesangial IgG deposition are risk factors for hypertension and renal failure in early IgA nephropathy. Am J Kidney Dis 31 (1998) 962-970
15. Kanauchi M., Nishioka H., and Hashimoto T. Oxidative DNA damage and tubulointerstitial injury in diabetic nephropathy. Nephron 91 (2002) 327-329
16. Lai K.N., Chan L.Y., and Leung J.C. Mechanisms of tubulointerstitial injury in IgA nephropathy. Kidney Int 94 Suppl (2005) S110-S115
17. Pel Prete P., Gambaro G., Lupo A., Anglani F., Brezzi B., Magistroni R., Graziotto R., Furci L., Modena F., Bernich P., Albertazzi A., D'Angelo A., and Maschio G. Precocious activation of genes of the rennin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney Int 64 (2003) 149-159
18. Ogawa-Miyake C., Miyazaki M., Abe K., Harada M., Ozono Y., Sakai H., Koji T., and Kohno S. Tissue-specific expression of rennin-angiotensin system components in IgA nephropathy. Am J Nephrol 25 (2005) 1-12
19. Kanno Y., Okada H., Yamaji Y., Nakazato Y., and Suzuki H. Angiotensin-converting-enzyme-inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation. Q J Med 98 (2005) 199-203
20. Horita Y., Tadokoro M., Taura K., Suyama N., Taguchi T., Miyazaki M., and Kohno S. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertens Res 27 (2004) 963-970
21. Yoshida K., and Kohzuki M. Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist. Cadiovasc Drug Rev 22 (2004) 285-308
22. Matotham K., Tanaka T., Matsumoto M., Ohse T., Miyata T., Inagi R., Kurokawa K., Fujita T., and Nangaku M. Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 15 (2004) 1277-1288
23. Fliser D., Wagner K.K., Loos A., Tsikas D., and Haller H. Chronic angiotensin II receptor blockade reduces renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 16 (2005) 1135-1140
24. Izuhara Y., Nangaku M., Inagi R., Tominaga N., Aizawa T., Kurokawa K., van Ypersele de Strihou C., and Miyata T. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 16 (2005) 3631-3641
25. Kurata A., Nishizawa H., Kihara S., Maeda N., Sonoda M., Okada T., Ohashi K., Hibuse T., Fujita K., Yasui A., Hiuge A., Kumada M., Kuriyama H., Shimomura I., and Funahashi T. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 70 (2006) 1717-1724
26. Yasunari K., Maeda K., Nakamura M., Watanabe T., Yoshikawa J., and Asada A. Pharmacological and clinical studies with temocapril, an angiotensin converting enzyme inhibitor that is excreted in the bile. Cardiovasc Drug Rev 22 (2004) 189-198
27. Nakamura T., Ushiyama C., Suzuki S., Hara M., Shimada N., Sekizuka K., Ebihara I., and Koide H. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol 20 (2000) 373-379
28. Hemmelder M.H., de Zeeuw D., and de Jong P.E. Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease. Nephrol Dial Transplant 14 (1999) 98-104
29. Russo D., Piani A., Balletta M.M., Nicola L.D., Savino F.A., Andreucci M., and Minutolo R. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33 (1999) 851-856
30. Nakamura T., Ushiyama C., Osada S., Takahashi Y., Shimada N., Ebihara I., and Koide H. Combination therapy of trandolapril and candesartan cilexetil reduces microalbuminuria and urinary endothelin-1 excretion in patients with type 2 diabetes. Clin Exp Nephrol 6 (2002) 135-139